Well hoping that Avtar Dhillon who owns 7 million shares might want to make sure funding is in place, Well I would hope so to say the least.
Graphene was made in a lab in 2003, but by 2014, it reportedly reached $9 million in sales predominately in electronics, battery energy and semiconductors. Graphene is 100 times stronger than steel by weight and efficiently conducts heat and electricity. It’s a new material that can store bits of small energy or make battery terminals more efficient.
Scientists at the University of Manchester, England decided to use graphene in a completely different way: to neutralize cancer stem cells (CSC) and not harm other cells.
The scientists used a modified version of graphene oxide flakes on six kinds of cancer cells where it hurts cancers the most, in the stem cells. They discovered that it acts as an anti-cancer agent that selectively targets stem cells. With cancer, stem cells are the origin for tumors, but they also withstand radiation, chemotherapy and surgery and typically are known to re-seed a tumor, even when it looks like it has been eradicated.
A tidbit from Monty Fool.....n phase 1 trials of Hodgkin lymphoma patients, for example, Opdivo produced an overall response rate of 87%, which was better than Keytruda's 66% response rate. But 21% of the patients who got Keytruda had a complete response, better than Opdivo's 17%. It's impossible to guess from that data which drug is going to look better in larger late-stage trials, let alone which drug doctors will eventually favor.
And even the current trials testing the drugs as monotherapies aren't likely to give a full picture of their long-term potential, because the drugs will eventually be used as combination treatments with other cancer drugs. That'll open up even more indications, and the drugs won't necessarily be competing with each other.
Both companies have already set up some partnerships to test combinations with drugs from other companies, and I expect more will follow. If you want to try to predict a long-term winner, keep track of the number of drug-combination trials the companies run, as it'll give some indication of the potential addressable market for the drugs.
But in recent years, the biotech industry has become an attractively rewarding sector for investors as the FDA bolstered its system to accelerate its approval process, particularly in the case of life-saving drugs. That was in large part due to the advance and fast progress by the biotrech companies in producing new and novel treatments for a variety of diseases.
“Breakthroughs in everything, from diagnostics to cancer immunotherapy” have resulted in a “renaissance” in biotechnology that’s now under way, says biotech analyst Jason Kolbert, senior managing director and head of Healthcare Research at Maxim Group. Today, “better clinical science is translating into earlier ‘proof of concept’ has made regulatory approvals more predictable,” he notes.
Kolbert expects this “paradigm shift” to translate into a higher valuation for the sector, “driven by better products with greater efficacy and fewer upside effects” which in turn has resulted in a higher rate of regulatory approvals.
“The fact that the number of FDA approvals has been trending positively each year is a great sign for the biotechnology space,” argues Kolbert. Not only does the industry help produce
NEW YORK (The Deal) -- Bristol-Myers Squibb (BMY) said Monday it would acquire venture-backed Flexus Biosciences for up to $1.25 billion in an effort to expand its cancer treatment pipeline.
Terms of the deal call for New York-based Bristol-Myers to make an $800 million upfront payment for the target and to make up to $450 million in development milestone payments. Flexus, based in San Carlos, Calif., has raised $38 million from investors including Kleiner Perkins Caufield & Byers, Column Group and Celgene (CELG) .
Flexus is focused on the development of novel anti-cancer therapies, including a preclinical small molecule inhibitor that is targeted for a U.S. Food and Drug Administration application filing in the second half of this year. The company is focused on targeting enzymes expressed by many tumor cells that suppress T-cell function, limiting the body's ability to attack and destroy tumors
If you believe hold on, if your trying to keep the price do your magic. The end game is what do you want out of it? nothing more or less . to each their own and just remember if your in the stock because you believe and would like it to go than ask yourself this, why are those here who are trying to keep it down. The truth is it's a game. you in or out?
“We’re excited, because it’s taken 100 years to get to this point,” Pierce says. “Even if only a subpopulation responds to the therapy, the patients respond for a long time. Now we can use biomarkers to tailor studies that will help to increase the response rate.” n
TORONTO, Jan. 22 /PRNewswire-FirstCall/ - Mina Mar Group Inc. www.minamargroup.com/ (MMG) and Mina Mar Marketing Group www.minamargroup.net/ (MMMG) inform the public that the courts ruled in the favour of Mina Mar Group in slander lawsuit against Investors Hub.
The authors show that in surgically created wounds penetrating the full thickness of rat livers, which are highly vascularized parenchymal organs, administration of AC5 resulted in rapid cessation of bleeding within a similar time period whether or not the animals were previously treated with therapeutic amounts of heparin. Furthermore, in animals treated with heparin, the use of AC5 to control bleeding resulted in an average reduction in bleeding time of approximately 98% when compared to a control. It was also reported that a microscopic analysis of the AC5-treated wound site demonstrated that AC5 completely filled the wound without causing identifiable negative effects on the tissues or blood cells with which it came into direct contact. The authors note that the utility of AC5 in the presence of anticoagulants may lead to a safer option to perform surgical procedures without having to discontinue the anticoagulant, and AC5 may facilitate the speed of surgery while safely and rapidly stopping bleeding.